In exchange for a partnership, biopharma companies should realize tangible benefits in terms of both pricing and delivery. Openly asking for additional benefits or highlighting concerns around pricing, KPIs and experiences is critical, as is tracking of the CRO partners’ ability to address these concerns.
Lastly, it is a substantial mutual benefit for biopharma companies to share their upcoming pipeline and potential award with the CRO so enable optimal study startup and resource planning.